MorphoSys AG buy geldnutzer
Summary
This prediction ended on 05.11.21 with a price of €40.63. The BUY prediction by geldnutzer for MorphoSys AG performed very badly with a performance of -39.95%. geldnutzer has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
MorphoSys AG | - | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
Comments by geldnutzer for this prediction
In the thread Morphosys AG diskutieren
geldnutzer stimmt dem Sentiment von 'Sell' nicht zu
geldnutzer stimmt am 16.07.2017 dem Sell-Gesamtsentiment mit dem Kursziel 65.7€ nicht zu.
In the thread Trading Morphosys AG